echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > AACR 2021: Anti-CD47 antibody AO-176 treats solid tumors and multiple myeloma, with positive results in preclinical trials

    AACR 2021: Anti-CD47 antibody AO-176 treats solid tumors and multiple myeloma, with positive results in preclinical trials

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Biotechnology company Arch Oncology announced today that it presented the latest preclinical data of AO-176 at the American Association for Cancer Research (AACR) annual meeting.


    AO-176 is a humanized anti-CD47 IgG2 antibody.


    The important thing for immunity is that AO-176 preferentially binds to tumor cells instead of normal cells, and more effectively binds to tumors in an acidic microenvironment (low pH).


    Lymphoma

     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.